6.
Donovan-Lepore A, Jaeger J, Czobor P, Abdelmessih S, Berns S
. Quantitative craniofacial anomalies in a racially mixed schizophrenia sample. Biol Psychiatry. 2005; 59(4):349-53.
DOI: 10.1016/j.biopsych.2005.06.034.
View
7.
DeRosse P, Funke B, Burdick K, Lencz T, Ekholm J, Kane J
. Dysbindin genotype and negative symptoms in schizophrenia. Am J Psychiatry. 2006; 163(3):532-4.
DOI: 10.1176/appi.ajp.163.3.532.
View
8.
Buckland P, Hoogendoorn B, Guy C, Smith S, Coleman S, ODonovan M
. Low gene expression conferred by association of an allele of the 5-HT2C receptor gene with antipsychotic-induced weight gain. Am J Psychiatry. 2005; 162(3):613-5.
DOI: 10.1176/appi.ajp.162.3.613.
View
9.
Lencz T, Smith C, McLaughlin D, Auther A, Nakayama E, Hovey L
. Generalized and specific neurocognitive deficits in prodromal schizophrenia. Biol Psychiatry. 2005; 59(9):863-71.
DOI: 10.1016/j.biopsych.2005.09.005.
View
10.
Hirvonen J, van Erp T, Huttunen J, Aalto S, Nagren K, Huttunen M
. Increased caudate dopamine D2 receptor availability as a genetic marker for schizophrenia. Arch Gen Psychiatry. 2005; 62(4):371-8.
DOI: 10.1001/archpsyc.62.4.371.
View
11.
Buckley P, Dean D, Bookstein F, Han S, Yerukhimovich M, Min K
. A three-dimensional morphometric study of craniofacial shape in schizophrenia. Am J Psychiatry. 2005; 162(3):606-8.
DOI: 10.1176/appi.ajp.162.3.606.
View
12.
Gardner M, Gonzalez-Neira A, Lao O, Calafell F, Bertranpetit J, Comas D
. Extreme population differences across Neuregulin 1 gene, with implications for association studies. Mol Psychiatry. 2005; 11(1):66-75.
DOI: 10.1038/sj.mp.4001749.
View
13.
Velakoulis D, Wood S, Wong M, McGorry P, Yung A, Phillips L
. Hippocampal and amygdala volumes according to psychosis stage and diagnosis: a magnetic resonance imaging study of chronic schizophrenia, first-episode psychosis, and ultra-high-risk individuals. Arch Gen Psychiatry. 2006; 63(2):139-49.
DOI: 10.1001/archpsyc.63.2.139.
View
14.
Burdick K, Hodgkinson C, Szeszko P, Lencz T, Ekholm J, Kane J
. DISC1 and neurocognitive function in schizophrenia. Neuroreport. 2005; 16(12):1399-402.
DOI: 10.1097/01.wnr.0000175248.25535.f6.
View
15.
Friedman J
. Historical perspective on movement disorders. J Clin Psychiatry. 2004; 65 Suppl 9:3-8.
View
16.
Borgwardt S, Radue E, Gotz K, Aston J, Drewe M, Gschwandtner U
. Radiological findings in individuals at high risk of psychosis. J Neurol Neurosurg Psychiatry. 2006; 77(2):229-33.
PMC: 2077602.
DOI: 10.1136/jnnp.2005.069690.
View
17.
Fukui N, Muratake T, Kaneko N, Amagane H, Someya T
. Supportive evidence for neuregulin 1 as a susceptibility gene for schizophrenia in a Japanese population. Neurosci Lett. 2005; 396(2):117-20.
DOI: 10.1016/j.neulet.2005.11.015.
View
18.
Lieberman J, Stroup T, McEvoy J, Swartz M, Rosenheck R, Perkins D
. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005; 353(12):1209-23.
DOI: 10.1056/NEJMoa051688.
View
19.
Neugebauer R
. Accumulating evidence for prenatal nutritional origins of mental disorders. JAMA. 2005; 294(5):621-3.
DOI: 10.1001/jama.294.5.621.
View
20.
Milev P, Ho B, Arndt S, Andreasen N
. Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first-episode study with 7-year follow-up. Am J Psychiatry. 2005; 162(3):495-506.
DOI: 10.1176/appi.ajp.162.3.495.
View